The Prophylactic Treatment of COVID-19 in a Renal Failure and Hodgkin Lymphoma Patient with Convalescent Plasma
International Journal of Research and Reports in Hematology,
COVID-19 is a viral infectious disease that is thought to have emerged from an animal market in Wuhan, People's Republic of China, in December 2019, and subsequently caused a pandemic. Despite the fact that one year has passed since the onset of the epidemic and many treatment agents have been tried, there is still no approved treatment. Convalescent plasma therapy is a passive immunization method and holds promise in the treatment of COVID-19. In this study, we observed that asymptomatic COVID-19 infection was effectively treated with convalescent plasma in a young patient with a diagnosis of Hodgkin lymphoma, acute renal failure also who received R-DHAP (Rituximab – Cisplatin – Cytarabine - Dexamethasone) chemotherapy treatment. We think that this treatment may be more effective when it is administered in an earlier stage of disease in asymptomatic patients.
- convalescent plasma
- hodgkin lymphoma
How to Cite
Abstract View: 105 times
PDF Download: 28 times